维普期刊资源整合服务平台（V6.5）

284篇 您的检索式：作者名="Meropol"

选中清除导出查看参考文献查看引证文献引用追踪共15页首页上一页第1页下一页末页 /15 跳转

	题名	作者	年代	出处	被引量
1	PhaseI pharma- cokinetie and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand recep- tor显示文摘	Tolcher AW Mita M Meropol NJ etal	2007	J Clin Oncol2007，25，：	1
2	UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan显示文摘	Carlini LE Meropol NJ Bever J	2005	Clin Cancer Res2005，11，：	1
3	Accomplishments in 2008 in the treatment of advanced metastatic colorectal cancer 显示文摘	Goldberg RM Meropol NJ Tabemero J	2009	Castrointest Cancer Res2009，3，2：	1
4	Phase Ⅱ trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	SALTZ L B MEROPOL N J LOEHRER P J Sr	2004	J Clin Oncol2004，22，7：	1
5	Phase lI trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol N J Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
6	Preliminary studies of a novel oral fluoropyrimidine carbamate:capecitabine显示文摘	Budman DR Meropol NJ Reigner B	1998	J Clin Oncol1998，16，6：	1
7	Development of new agents for the treatment of advanced colorectal cancer 显示文摘	Lewis NL Meropol NJ	2003	Clin Colorectal Cancer2003，3，：	1
8	Bevacizumab incombination with oxaliplatin, fluorouracil, and leucovorin (FOL2FOX4) for previously treated metastatic coloreetal cancer:resultsfrom the Eastern Cooperative Oncology Group Study E3200显示文摘	Giantonio B J Catalano P J Meropol NJ	2007	J Clin Oncol2007，25，12：	1
9	Bevacizumab in combination with oxaliplatin fluorouracil,and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer:results from the Eastern Cooperative Oncology Group Study E3200显示文摘	Giantonio BJ Catalano PJ Meropol NJ		0，，12：	1
10	Oral fluoropyrimidines in the treatment of colorectal cancer显示文摘	Meropol NJ		0，，：	1
11	Relationship among circulating tumor cells, CEA and overall survival in patients with metastatic colorectal cancer显示文摘	AGGARWAL C MEROPOL N J PUNT C J		0，，：	1
12	Colon cancer recurrence:insights from the interface between epidemiology,laboratory sci-ence,and clinical medicine显示文摘	Meropol NJ Berger NA		0，，22：	1
13	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel 显示文摘	Rothenberg ML Meropol NJ Poplin EA	2001	J Clin Oncol2001，19，18：	1
14	Mortality associated with irinotecan plus bolus fluorouracil/leucovorin: summary findings of an independent panel显示文摘	Rothenberg ML Meropol N J Poplin EA	2001	J Clin Oncol2001，19，18：	1
15	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol NJ Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
16	Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 显示文摘	GIANTONIO B J CATALANO P J MEROPOL N J	2007	J Clin Oncol2007，25，12：	1
17	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L Meropol NJ		0，，：	1
18	Phase II trial of cetuximab in patients with refraetory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz L B Meropol N J Loehrer P J	2004	J Clin Oncol2004，22，7：	1
19	Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor显示文摘	Saltz LB Meropol NJ Loehrer PJ Sr	2004	J Clin Oncol2004，22，7：	1
20	Ac- complishments in 2008 in the treatment of advaffced metastatic colorectal cancer显示文摘	Goldberg RM Meropol NJ Tabernero J	2009	Gastrointest Cancer Res2009，3，2：	1

返回顶部每页显示：

共15页首页上一页第1页下一页末页 /15 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示